TRCT
RPTX

Tower Research Capital (TRC)’s Repare Therapeutics RPTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,356
Closed -$4.67K – 5565
2025
Q2 		$4.67K Buy
+3,356
New +$4.38K ﹤0.01% 4286
2025
Q1 		– Sell
-34,423
Closed -$45.1K – 5690
2024
Q4 		$45.1K Buy
34,423
+23,127
+205% +$68.9K ﹤0.01% 2623
2024
Q3 		$38.9K Buy
11,296
+10,777
+2,076% +$35.5K ﹤0.01% 2866
2024
Q2 		$1.71K Sell
519
-3,457
-87% -$12.3K ﹤0.01% 5104
2024
Q1 		$18.7K Buy
3,976
+3,776
+1,888% +$24.2K ﹤0.01% 3058
2023
Q4 		$1.46K Sell
200
-5,926
-97% -$33.2K ﹤0.01% 5377
2023
Q3 		$74K Buy
6,126
+3,899
+175% +$40.2K ﹤0.01% 2221
2023
Q2 		$23.6K Sell
2,227
-9,089
-80% -$93.6K ﹤0.01% 3237
2023
Q1 		$111K Buy
11,316
+9,529
+533% +$109K ﹤0.01% 1775
2022
Q4 		$26K Sell
1,787
-7,548
-81% -$113K ﹤0.01% 2887
2022
Q3 		$113K Buy
+9,335
New +$120K ﹤0.01% 2463
2022
Q2 		– Sell
-4,909
Closed -$70K – 6455
2022
Q1 		$70K Buy
4,909
+4,898
+44,527% +$72.6K ﹤0.01% 2460
2021
Q4 		$0 Sell
11
-185
-94% -$4.36K ﹤0.01% 6509
2021
Q3 		$5K Sell
196
-3,340
-94% -$108K ﹤0.01% 4879
2021
Q2 		$110K Buy
3,536
+311
+10% +$10.2K ﹤0.01% 2355
2021
Q1 		$98K Buy
3,225
+1,419
+79% +$48.2K ﹤0.01% 2601
2020
Q4 		$62K Buy
1,806
+1,804
+90,200% +$53.9K ﹤0.01% 2880
2020
Q3 		$0 Sell
2
-871
-100% -$23.1K ﹤0.01% 5057
2020
Q2 		$27K Buy
+873
New +$28K ﹤0.01% 3516

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

Tower Research Capital (TRC)'s RPTX Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Repare Therapeutics (RPTX) in Q3 2025, closing a stake of 3,356 shares — an estimated $4.67K sold.

Tower Research Capital (TRC) first reported a position in RPTX in Q2 2020 and held it in 19 quarters. The position peaked at $113K in Q3 2022. 45 funds tracked by Wall St. Rank hold RPTX as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining Repare Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 3,356 Repare Therapeutics shares in Q3 2025, an estimated $4.67K.
  • Tower Research Capital (TRC) first reported a position in Repare Therapeutics in Q2 2020 and held it in 19 quarters.
  • Tower Research Capital (TRC)'s Repare Therapeutics position peaked at $113K in Q3 2022.
  • 45 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.